Trial · NCT01429077
Augmenting Language Therapy for Aphasia: Levodopa
NCT01429077, Phase 2, Phase 3, Completed, Shirley Ryan AbilityLab; results first posted 2013-11-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Augmenting Language Therapy for Aphasia: Levodopa. Trials, record NCT01429077. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01429077
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Augmenting Language Therapy for Aphasia: Levodopa
- NCT number
- NCT01429077
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 36 participants, actual
- Lead sponsor
- Shirley Ryan AbilityLab
- Conditions
- Nonfluent Aphasia, Stroke
- Interventions
- levodopa/carbidopa, Placebo comparator
- First posted
- 2011-09-05
- Last updated
- 2013-12-25
- Results first posted
- 2013-11-28
- Limitations and caveats
* Dosage and timing of the L-dopa in relation to the behavioral treatment may not have been optimum.~* Efficacy of the behavioral treatment in both arms may have overridden the enhancing effect of the l-dopa in one arm
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Language Quotient (LQ) on the Western Aphasia Battery | Change from Baseline in Western Aphasia Battery LQ at 6 weeks | Includes a measure of auditory comprehension, oral expression, reading and written expression skills. The scale ranges from 1 - 100 with 100 being better. The change or gain score from baseline to immediately post-treatment (at 6 weeks) is reported. The larger the change score, the greater the improvement. |
| Secondary | Functional Communication Skills | Change from Baseline in functional communication skills at 6 weeks | Scores derived from language sample analyses |
| Secondary | Participation in Everyday Activities | Change from Baseline in participation in everyday activities at 6 weeks | Measures on CETI, QCL,BOSS, CCRSA. |
| Secondary | Western Aphasia Battery - Reading and Writing Scores | Change from Baseline in Western Aphasia Battery Reading and Writing scores at 6 weeks | |
| Secondary | Western Aphasia Battery Aphasia Quotient (Maintenance) | Change in Western Aphasia Battery AQ from 6 weeks to 12 weeks | |
| Secondary | Western Aphasia Battery Reading and Writing Scores (Maintenance) | Change in WAB Reading and Writing Skills from 6 weeks to 12 weeks | |
| Secondary | Functional Communication Skills (Maintenance) | Change in functional communication skills from 6 weeks to 12 weeks | |
| Secondary | Participation in Everyday Activities (Maintenance) | Change in participation in everyday activities from 6 weeks to 12 weeks |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Language Quotient (LQ) on the Western Aphasia Battery | Change from Baseline in Western Aphasia Battery LQ at 6 weeks | units on a scale | MEAN | |
| SECONDARY | Functional Communication Skills | Change from Baseline in functional communication skills at 6 weeks | |||
| SECONDARY | Participation in Everyday Activities | Change from Baseline in participation in everyday activities at 6 weeks | |||
| SECONDARY | Western Aphasia Battery - Reading and Writing Scores | Change from Baseline in Western Aphasia Battery Reading and Writing scores at 6 weeks | |||
| SECONDARY | Western Aphasia Battery Aphasia Quotient (Maintenance) | Change in Western Aphasia Battery AQ from 6 weeks to 12 weeks | |||
| SECONDARY | Western Aphasia Battery Reading and Writing Scores (Maintenance) | Change in WAB Reading and Writing Skills from 6 weeks to 12 weeks | |||
| SECONDARY | Functional Communication Skills (Maintenance) | Change in functional communication skills from 6 weeks to 12 weeks | |||
| SECONDARY | Participation in Everyday Activities (Maintenance) | Change in participation in everyday activities from 6 weeks to 12 weeks |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Language Quotient (LQ) on the Western Aphasia Battery | Levodopa/Carbidopa | 3.16 | Standard Deviation 3.63 | units on a scale | |
| Language Quotient (LQ) on the Western Aphasia Battery | Inactive Pill | 2.59 | Standard Deviation 3.41 | units on a scale |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Levodopa | 19 | |
| Overall Study | STARTED | Inactive Pill | 17 | |
| Overall Study | Completed 6-week Intervention | Levodopa | 19 | |
| Overall Study | Completed 6-week Intervention | Inactive Pill | 17 | |
| Overall Study | COMPLETED | Levodopa | 19 | |
| Overall Study | COMPLETED | Inactive Pill | 14 | |
| Overall Study | NOT COMPLETED | Levodopa | 0 | |
| Overall Study | NOT COMPLETED | Inactive Pill | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Levodopa | ||
| Total, all-cause mortality | Inactive Pill | ||
| Total, other adverse events | Levodopa | 0 | 19 |
| Total, other adverse events | Inactive Pill | 0 | 14 |
| Total, serious adverse events | Levodopa | 0 | 19 |
| Total, serious adverse events | Inactive Pill | 0 | 14 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Levodopa vs Inactive Pill: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01429077
GET https://conductscience.org/api/trials/v1/NCT01429077/registered